Japan’s Risk Management Plan Will Require Tinkering To New Drug Applications
This article was originally published in PharmAsia News
New rules take effect April 2013, but uncertainty remains within the PMDA and industry on how RMP guidance will evolve and shape development in the years ahead.
You may also be interested in...
Can generic manufacturers use patented elements of a drug distribution plan? Will FDA accept an alternative REMS program? Will brand companies have to provide access to their products? As the number of brand products subject to REMS grows, so do the unanswered questions for generic firms.
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.